Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Oyster Point Pharma, Inc. | q4-20ex322.htm |
| EX-31.2 - EX-31.2 - Oyster Point Pharma, Inc. | q4-20ex312.htm |
| EX-31.1 - EX-31.1 - Oyster Point Pharma, Inc. | q4-20ex311.htm |
| EX-23.1 - EX-23.1 - Oyster Point Pharma, Inc. | q4-20ex231.htm |
| EX-10.9 - EX-10.9 - Oyster Point Pharma, Inc. | exhibit109.htm |
| 10-K - 10-K - Oyster Point Pharma, Inc. | oyst-20201231.htm |
Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Oyster Point Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Nau, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and | |||||||
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. | |||||||
Date: February 18, 2021 | By: | /s/ Jeffrey Nau | ||||||
| Jeffrey Nau, Ph.D., M.M.S. | ||||||||
| President and Chief Executive Officer | ||||||||
| (Principal Executive Officer) | ||||||||